Dendrimer nanoparticles (DNPs), which have been studied extensively as drug delivery systems, can be synthesized easily with zirconium without chelators. A UV/Vis spectrophotometer and a Dynamic Light Scattering (DLS) analysis were used to confirm the synthesis and the particle size of the composite. Compound B synthesized using a chelator compound was found to be more complex than compound A, and natZr was found to bind at a low yield through Scanning Electron Microscopy-Energy Dispersive X-ray Spectrometer (SEM-EDS) and Inductively Coupled Plasma-Mass Spectrometer (ICP-MS). In PBS (1×), The binding was confirmed to be strong and stable at 99% stability or more. The stability to human serum was very good with a value of about 98%. The stability of the bound 89 Zr was confirmed to be stable for 160 minutes through the evaluation of serum stability. Using CT-26 and MDA-MB-231, We also were able to confirm the difference in the cell uptake of 89Zr-DNPs. After 24 hours, a high cell uptake of close to 40% was observed. Positron Emission Tomography (PET) images were observed, it was confirmed that no accumulation of 89 Zr-DNPs in the bones and its stability in the body.

中文翻译：

---

Zr-89 标记的 PAMAM 树枝状聚合物 5G，不含用于癌症诊断剂的螯合剂

树枝状大分子纳米粒子 (DNP) 已作为药物递送系统进行了广泛研究，可以在没有螯合剂的情况下使用锆轻松合成。紫外/可见分光光度计和动态光散射 (DLS) 分析用于确认复合材料的合成和粒径。发现使用螯合剂化合物合成的化合物 B 比化合物 A 更复杂，并且通过扫描电子显微镜-能量色散 X 射线光谱仪 (SEM-EDS) 和电感耦合等离子体质谱仪发现 natZr 以低产率结合(ICP-MS)。在 PBS (1x) 中，结合被证实在 99% 或更高的稳定性下是强而稳定的。对人血清的稳定性非常好，约为98%。通过血清稳定性的评价，证实结合的89 Zr的稳定性在160分钟内是稳定的。使用 CT-26 和 MDA-MB-231，我们还能够确认 89Zr-DNP 的细胞摄取差异。24 小时后，观察到接近 40% 的高细胞摄取。观察正电子发射断层扫描（PET）图像，证实骨骼中没有89个Zr-DNPs的积累，并且在体内稳定。